Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Abbott Laboratories    ABT

News SummaryMost relevantAll newsSector newsTweets 

European Medical Group Changes Drug Data-Release Policy After Criticism

share with twitter share with LinkedIn share with facebook
share via e-mail
03/22/2012 | 06:28pm CEST
   By Peter Loftus 

A European medical society has changed its plans for releasing results of clinical studies of liver-disease therapies after some critics said the original plan would have amounted to selective disclosure to certain investors.

The studies are expected to include potentially market-moving results of trials involving hepatitis C drugs in development at Abbott Laboratories (>> Abbott Laboratories), Bristol-Myers Squibb Co. (>> Bristol Myers Squibb Co.) and Gilead Sciences Inc. (GILD).

The European Association for the Study of the Liver now plans to publicly release summaries of most of the studies online April 4, two weeks ahead of the association's International Liver Congress meeting in Barcelona.

Under the new policy, certain studies selected to be highlighted by EASL's press office won't be made available publicly until the date and time of their presentation at the conference, which runs April 18-22. EASL didn't say which studies will be selected. However, EASL said they won't be made available in advance to non-media conference participants before the embargoes lift.

Previously, EASL had planned to make the summaries available online Thursday, but only accessible to EASL members and those registered for the conference, which includes analysts and investors. EASL also previously planned to prohibit media registered to attend the conference from reporting on the summaries until the conference.

Critics of the policy, including TheStreet.com reporter Adam Feuerstein, said the original plans amounted to selective disclosure by providing material information to people who paid to attend the conference, while unfairly leaving others in the dark.

"EASL is making these changes in light of recent criticism of its proposed policy, which suggests that 'selective distribution' of officially accepted clinical data in advance of the Congress would make our proposed embargo policy untenable," EASL said in a written statement Thursday.

The presentation of drug data at medical meetings has long posed a conundrum for companies and investors. Some conferences have made changes in their policies to address concerns.

The American Society of Clinical Oncology, for instance, used to distribute study summaries to participants at its annual meeting weeks ahead of the conference, but prohibit media from reporting the contents until the conference.

ASCO has since changed its policy so that now most summaries are posted publicly online a few weeks before the annual scientific meeting, while certain featured studies aren't publicly disclosed until the meeting.

Scott Gottlieb, a physician and resident fellow at the American Enterprise Institute who has criticized certain medical meeting embargo policies, said EASL did the right thing.

"I think the days of conferences engaging in selective release of important study results are probably over," he said. "ASCO yielded to this truth, EASL did, and I suspect other major conferences will be that much more reluctant to now buck these precedents."

-By Peter Loftus, Dow Jones Newswires; +1-215-982-5581; [email protected]

Stocks mentioned in the article : Abbott Laboratories, Bristol Myers Squibb Co.
share with twitter share with LinkedIn share with facebook
share via e-mail
05/26 ABBOTT LABS : A genomic disease management company, engages in the development a..
05/25 ABBOTT LABORATORIES : An Application for the Trademark "EAS PRO SCIENCE" Has Bee..
05/25 ABBOTT LABORATORIES : Trademark Application for "IDENTIFY WITH US" Filed by Abbo..
05/25 ABBOTT LABORATORIES : Trademark Application for "HI-TORQUE INTERMEDIATE" Filed b..
05/25 ABBOTT LABORATORIES : An Application for the Trademark "YUCK-O-METER" Has Been F..
05/25 ABBOTT LABORATORIES : An Application for the Trademark "XIENCE PRIME" Has Been F..
05/24 ABBOTT LABORATORIES : 26 patients have died after replacing controller for Abbot..
05/24 ALERE : Announces Update on Form 10-K and Provides Preliminary Unaudited Financi..
05/23 ABBOTT LABORATORIES : Kahira Pharmaceuticals to produce Brufen for Abbott
More news
Sector news : Pharmaceuticals - NEC
05/26DJSUN PHARMACEUTICAL INDUSTRIES : Pharma 4Q Profit Falls 13.6%
05/24 JOHNSON & JOHNSON : J&J settles drug manufacturing probe by U.S. states for $33 ..
05/24 FTSE edges up helped by M&S, but miners weigh
05/23DJMERCK : FDA OKs Merck's Keytruda to Treat Cancers With Genetic Defects -- Update
05/23DJMERCK : FDA Approves Merck's Keytruda to Treat Cancers With Genetic Defects
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
05/24 Abbott recalls HeartMate II LVAS controller due to risk during controller exc..
05/19 Dividend Yields Also Drown In Floods
05/17 Healthcare firms fail to swim against the tide; all sectors down
05/16 Premarket analyst action - healthcare
05/13 THE OBESITY EPIDEMIC : Are Roche And Bristol-Myers Sitting On A Mighty Prospect?
Financials ($)
Sales 2017 26 370 M
EBIT 2017 5 716 M
Net income 2017 2 939 M
Debt 2017 16 513 M
Yield 2017 2,46%
P/E ratio 2017 25,70
P/E ratio 2018 20,67
EV / Sales 2017 3,52x
EV / Sales 2018 3,27x
Capitalization 76 265 M
More Financials
Duration : Period :
Abbott Laboratories Technical Analysis Chart | ABT | US0028241000 | 4-Traders
Full-screen chart
Technical analysis trends ABBOTT LABORATORIES
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 48,1 $
Spread / Average Target 9,4%
Consensus details
EPS Revisions
More Estimates Revisions
Miles D. White Chairman & Chief Executive Officer
Brian B. Yoor Chief Financial Officer & Executive VP-Finance
Roxanne Schuh Austin Independent Director
Jim Farrell Independent Director
Samuel C. Scott Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON10.68%343 545
ROCHE HOLDING LTD.14.88%236 038
NOVARTIS AG6.68%212 104
PFIZER INC.-1.32%191 517
MERCK & CO., INC.10.48%177 895
More Results